Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.

Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2008
Size (employees)
287 (est)
Website
agios.com
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
88 Sidney St

Agios Pharmaceuticals Data and Metrics

Agios Pharmaceuticals Financial Metrics

Agios Pharmaceuticals's revenue was reported to be $10.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

10.5 m

Net income (Q1, 2017)

(66.2 m)

EBIT (Q1, 2017)

(67 m)

Market capitalization (22-Aug-2017)

2.7 b

Cash (31-Mar-2017)

200.3 m
Agios Pharmaceuticals's current market capitalization is $2.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25.5 m65.4 m59.1 m69.9 m

Revenue growth, %

156%(10%)18%

EBIT

(38.9 m)(54.1 m)(118.7 m)(201 m)

EBIT margin, %

(152%)(83%)(201%)(288%)

Interest income

55 k203 k968 k2.5 m

Pre tax profit

(117.7 m)(198.5 m)

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

8.4 m34.2 m13.2 m5.5 m31.3 m7 m9 m10.5 m

R&D expense

22.6 m25.5 m32.4 m36.4 m36 m44 m50.8 m60.6 m62.7 m

General and administrative expense

4.2 m5.2 m7 m8.9 m9.9 m10.8 m12.6 m11.9 m14.8 m

Operating expense total

26.7 m30.7 m39.4 m45.4 m46 m54.9 m63.4 m72.5 m77.6 m

EBIT

(18.3 m)3.2 m(5.2 m)(32.1 m)(40.5 m)(23.6 m)(56.5 m)(63.5 m)(67 m)

EBIT margin, %

(218%)(15%)(243%)(739%)(75%)(809%)(707%)(638%)

Interest income

34 k48 k238 k236 k218 k396 k517 k678 k881 k

Pre tax profit

(18.3 m)3.3 m

Income tax expense

(448 k)

Net Income

(18.3 m)3.7 m(5 m)(31.9 m)(40.3 m)(23.2 m)(56 m)(62.8 m)(66.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

71.6 m14 m71.8 m160.8 m

Accounts Receivable

2.3 m600 k

Inventories

2.5 m4.8 m8.7 m10.3 m

Current Assets

169.7 m359.5 m337.3 m559.9 m

PP&E

3.8 m6.4 m23.2 m25.3 m

Total Assets

201.2 m491.9 m420.1 m619.1 m

Accounts Payable

3.7 m11.1 m14.7 m17.1 m

Current Liabilities

36.9 m61.1 m52.9 m88.4 m

Additional Paid-in Capital

244.9 m591.3 m630.1 m842 m

Retained Earnings

(113.4 m)(166.9 m)(284.7 m)(483.2 m)

Total Equity

131.5 m424.4 m345.1 m358.6 m

Financial Leverage

1.5 x1.2 x1.2 x1.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

108.2 m70 m35.3 m72.5 m80 m39 m234 m285.5 m200.3 m

Current Assets

245.2 m247.6 m364.1 m390.2 m371.7 m329.5 m484.2 m600.9 m506.9 m

PP&E

3.2 m3.7 m14.3 m19.3 m21.1 m23 m25.1 m26.3 m24.1 m

Total Assets

272 m269.6 m474.3 m474.4 m449.1 m396.1 m557.6 m672 m557.3 m

Accounts Payable

5.4 m6.2 m12.6 m8.9 m9 m13.7 m18.4 m15.4 m16.2 m

Current Liabilities

44.6 m35.1 m36.4 m45.2 m49.8 m45.1 m67.3 m78 m82.4 m

Additional Paid-in Capital

344.5 m347.9 m598.5 m607.7 m619.5 m640.1 m652.6 m828 m857.1 m

Retained Earnings

(144 m)(140.3 m)(171.9 m)(203.8 m)(244.1 m)(307.9 m)(363.8 m)(426.7 m)(549.6 m)

Total Equity

200.5 m207.7 m426.8 m404.2 m375.7 m332.4 m289.1 m401.4 m307.4 m

Financial Leverage

1.4 x1.3 x1.1 x1.2 x1.2 x1.2 x1.9 x1.7 x1.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)

Depreciation and Amortization

1.4 m1.4 m3.3 m5.7 m

Accounts Receivable

(2.3 m)(1 m)

Accounts Payable

30 k7.6 m4.2 m3.5 m

Cash From Operating Activities

(56.4 m)(59.4 m)(76.9 m)38.6 m

Purchases of PP&E

(1.3 m)(2.2 m)(20.2 m)(9.9 m)

Cash From Investing Activities

(87.2 m)(333.3 m)128.3 m(119.4 m)

Cash From Financing Activities

123.9 m335.2 m6.4 m169.8 m

Income Taxes Paid

6 m6 m6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(18.3 m)3.7 m(5 m)(31.9 m)(40.3 m)(23.2 m)(56 m)(62.8 m)(66.2 m)

Accounts Payable

5.4 m6.2 m12.6 m8.9 m9 m13.7 m18.4 m15.4 m16.2 m
USDY, 2017

Revenue/Employee

36.6 k

Financial Leverage

1.8 x

Agios Pharmaceuticals Market Value History

Traffic Overview of Agios Pharmaceuticals

Agios Pharmaceuticals Online and Social Media Presence

Agios Pharmaceuticals News and Updates

Researchers at Yale have taken steps toward a ‘completely unexpected’ new way to treat brain cancer

Researchers at Yale think they've come up with a new way to treat a certain kind of brain tumor using a drug that's already been approved by the FDA. In a study published Wednesday in the journal Science Translational Medicine, the researchers outline a hypothesis for using…

Agios Pharmaceuticals Company Life and Culture

You may also be interested in